Aujourd’hui j’ai fait une journée à thème j’arrête l’esomeprazole qui coule dans les veines des 3/4 des patients en post-op de chirurgie digestive. Les internes de chir (que j’adore) m’ont regardé avec des yeux de merlans frits genre « i’ va pas mourir d’un ulcère dis ? »
J’espère que non. Voilà quelques pistes pour réfléchir à deux fois avant de prescrire un IPP non justifié :
(NB, la FDA a même lancé une alerte sur le risque de pneumonie avec les IPP)
update : IPP et insuffisance rénale aigüe par là
en passant
tiens encore un petit coup de pied dans les roubignoles des IPP https://t.co/Ty1MTAiEAD
— nfkb (@nfkb) September 19, 2016
858234
IXBBZN4Q
1
vancouver
50
default
3219
https://www.nfkb0.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EET995P8%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perazella%22%2C%22parsedDate%22%3A%222013-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPerazella%20MA.%20Proton%20pump%20inhibitors%20and%20hypomagnesemia%3A%20a%20rare%20but%20serious%20complication.%20Kidney%20Int.%202013%20Apr%3B83%284%29%3A553%26%23x2013%3B6.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proton%20pump%20inhibitors%20and%20hypomagnesemia%3A%20a%20rare%20but%20serious%20complication%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20A%22%2C%22lastName%22%3A%22Perazella%22%7D%5D%2C%22abstractNote%22%3A%22Proton%20pump%20inhibitors%20%28PPIs%29%20promote%20hypomagnesemia%20through%20loss%20of%20active%20Mg%282%2B%29%20absorption%20via%20transient%20receptor%20potential%20melastatin-6%20and%20-7%20%28TRPM6%5C%2F7%29.%20Danziger%20et%20al.%20confirm%20the%20association%20of%20PPIs%20with%20hypomagnesemia%20in%20patients%20hospitalized%20at%20a%20tertiary%20medical%20center.%20They%20found%20that%20patients%20taking%20PPIs%2C%20compared%20with%20those%20receiving%20histamine-2%20antagonists%20or%20no%20acid-suppressive%20medications%2C%20had%20a%20decline%20in%20serum%20Mg%282%2B%29%20after%20adjusting%20for%20several%20clinical%20and%20laboratory%20factors.%20The%20effect%20was%20seen%20only%20in%20those%20concomitantly%20receiving%20diuretics.%22%2C%22date%22%3A%22Apr%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fki.2012.462%22%2C%22ISSN%22%3A%221523-1755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22FZENQH3H%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Famularo%20et%20al.%22%2C%22parsedDate%22%3A%222013-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFamularo%20G%2C%20Gasbarrone%20L%2C%20Minisola%20G.%20Hypomagnesemia%20and%20proton-pump%20inhibitors.%20Expert%20Opin%20Drug%20Saf.%202013%20Sep%3B12%285%29%3A709%26%23x2013%3B16.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypomagnesemia%20and%20proton-pump%20inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Famularo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Gasbarrone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Minisola%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Proton%20pump%20inhibitors%20%28PPIs%29%20have%20been%20linked%20to%20clinically%20symptomatic%20hypomagnesemia.%5CnAREAS%20COVERED%3A%20We%20searched%20Medline%20database%20in%20all%20languages%20using%20%27proton-pump%20inhibitors%2C%20magnesium%2C%20hypomagnesemia%20and%20hypomagnesemic%20hypoparathyroidism%27%20as%20search%20terms%20and%20other%20articles%20were%20identified%20through%20searches%20of%20the%20files%20of%20the%20authors%20and%20reference%20lists%20from%20relevant%20articles.%20All%20patients%20presented%20with%20hypomagnesemic%20hypoparathyroidism%2C%20however%2C%20they%20rarely%20had%20life-threatening%20conditions%20such%20as%20malignant%20ventricular%20arrhythmias%20associated%20with%20prolonged%20QT%20interval%2C%20tetany%20and%20generalized%20seizures.%20Hypomagnesemia%20was%20seen%20with%20different%20PPIs%2C%20which%20could%20suggest%20a%20class%20effect%2C%20and%20was%20refractory%20to%20Mg%20replacement%20until%20PPIs%20were%20stopped.%20Hypomagnesemia%20may%20recur%20after%20re-challenge%20with%20the%20same%20or%20a%20different%20PPI%20and%20is%20not%20clearly%20dose-related.%20Mechanisms%20are%20poorly%20understood%20but%20PPI-induced%20hypochlorhydria%20does%20not%20seem%20involved.%20Carriers%20of%20TRPM6%5C%2F7%20mutations%20could%20be%20at%20risk.%5CnEXPERT%20OPINION%3A%20Although%20mechanism%20and%20incidence%20rate%20remain%20unclear%2C%20there%20seems%20little%20doubt%20that%20PPIs%20may%20cause%20hypomagnesemia.%20We%20should%20obtain%20blood%20Mg%20levels%20prior%20to%20initiation%20of%20PPIs%20when%20patients%20are%20expected%20to%20be%20on%20treatment%20for%20long%20period%20of%20time%20and%20in%20those%20with%20other%20potential%20causes%20of%20hypomagnesemia.%20Use%20of%20H2-blockers%20may%20be%20an%20appropriate%20alternative.%22%2C%22date%22%3A%22Sep%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1517%5C%2F14740338.2013.809062%22%2C%22ISSN%22%3A%221744-764X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22CEXJCTDG%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22El-Charabaty%20et%20al.%22%2C%22parsedDate%22%3A%222013%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EEl-Charabaty%20E%2C%20Saifan%20C%2C%20Abdallah%20M%2C%20Naboush%20A%2C%20Glass%20D%2C%20Azzi%20G%2C%20et%20al.%20Effects%20of%20proton%20pump%20inhibitors%20and%20electrolyte%20disturbances%20on%20arrhythmias.%20Int%20J%20Gen%20Med.%202013%3B6%3A515%26%23x2013%3B8.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20proton%20pump%20inhibitors%20and%20electrolyte%20disturbances%20on%20arrhythmias%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22El-Charabaty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chadi%22%2C%22lastName%22%3A%22Saifan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mokhtar%22%2C%22lastName%22%3A%22Abdallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Naboush%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Glass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Azzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yorg%22%2C%22lastName%22%3A%22Azzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahsan%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Baydoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chetana%22%2C%22lastName%22%3A%22Rondla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ninad%22%2C%22lastName%22%3A%22Parekh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22El-Sayegh%22%7D%5D%2C%22abstractNote%22%3A%22Several%20case%20reports%20have%20been%20written%20regarding%20the%20relationship%20between%20the%20use%20of%20proton%20pump%20inhibitors%20%28PPI%29%20and%20hypomagnesemia.%20Some%20of%20these%20reported%20cases%20have%20electrocardiogram%20abnormalities%20where%20electrolytes%20deficiencies%20were%20the%20contributing%20factor%20for%20these%20events.%20This%20study%20investigates%20the%20correlation%20between%20different%20arrhythmias%20and%20the%20use%20of%20PPI%20and%20hypomagnesaemia%20incidence.%20Four-hundred%20and%20twenty-one%20patients%20admitted%20to%20the%20critical%20care%20unit%20with%20unstable%20angina%2C%20non-ST%20elevation%20myocardial%20infarction%2C%20and%20ST-elevation%20myocardial%20infarction%20were%20included%20in%20this%20study.%20One-hundred%20and%20eighty-four%20patients%20%2843.8%25%29%20received%20PPI%20and%20237%20patients%20%2851.16%25%29%20did%20not%2C%20magnesium%20levels%20were%20low%20%28%3C1.8%20mg%5C%2FdL%29%20in%2095%20patients%20%2822.5%25%29%2C%20and%20167%20patients%20%2839.6%25%29%20developed%20arrhythmias.%20The%20P-values%20for%20the%20regression%20coefficient%20association%20for%20the%20use%20of%20PPI%20and%20the%20level%20of%20magnesium%20were%20P%20%3D%201.31e%28-29%29%20and%20P%20%3D%208e%28-102%29%2C%20respectively.%20The%20P-values%20indicate%20that%20there%20is%20a%20statistically%20significant%20association%20between%20the%20PPI%20use%2C%20magnesium%20levels%2C%20and%20the%20occurrence%20of%20cardiovascular%20events%2C%20with%20a%20strong%20correlation%20factor%20of%200.817.%20Patients%20receiving%20PPIs%20should%20be%20followed%20closely%20for%20magnesium%20deficiency%2C%20especially%20if%20they%20experience%20acute%20cardiovascular%20events%2C%20because%20this%20may%20contribute%20to%20worsening%20arrhythmias%20and%20further%20complications.%22%2C%22date%22%3A%222013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2147%5C%2FIJGM.S46932%22%2C%22ISSN%22%3A%221178-7074%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22SHIXDQD2%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wilhelm%20et%20al.%22%2C%22parsedDate%22%3A%222013-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EWilhelm%20SM%2C%20Rjater%20RG%2C%20Kale-Pradhan%20PB.%20Perils%20and%20pitfalls%20of%20long-term%20effects%20of%20proton%20pump%20inhibitors.%20Expert%20Rev%20Clin%20Pharmacol.%202013%20Jul%3B6%284%29%3A443%26%23x2013%3B51.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Perils%20and%20pitfalls%20of%20long-term%20effects%20of%20proton%20pump%20inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheila%20M%22%2C%22lastName%22%3A%22Wilhelm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%20G%22%2C%22lastName%22%3A%22Rjater%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pramodini%20B%22%2C%22lastName%22%3A%22Kale-Pradhan%22%7D%5D%2C%22abstractNote%22%3A%22This%20review%20summarizes%20the%20literature%20regarding%20long-term%20adverse%20effects%20of%20proton%20pump%20inhibitors%20%28PPIs%29.%20A%20PubMed%20search%20%281966%20to%20February%202013%29%20for%20English%20language%20studies%20was%20conducted%20using%20key%20terms%20PPI%3A%20omeprazole%2C%20esomeprazole%2C%20pantoprazole%2C%20lansoprazole%2C%20dexlansoprazole%2C%20rabeprazole%2C%20pneumonia%2C%20Clostridium%20difficile%2C%20osteoporosis%2C%20risk%20of%20fractures%2C%20thrombocytopenia%2C%20rhabdomyolysis%2C%20anemia%2C%20iron%20deficiency%2C%20hypomagnesemia%2C%20vitamin%20B%5Cu2081%5Cu2082%20and%20nephritis.%20The%20risk%20of%20pneumonia%20was%20increased%2027-39%25%20in%20short-term%20use%20of%20PPIs%20in%20three%20meta-analyses.%20C.%20difficile%20infections%20were%20also%20associated%20with%20the%20use%20of%20PPIs%20%28odds%20ratio%3A%202.15%3B%2095%25%20CI%3A%201.81-2.55%3B%20p%20%3C%200.00001%29.%20This%20effect%20appears%20to%20be%20dose%20related.%20The%20US%20FDA%20has%20recently%20issued%20a%20warning%20regarding%20fractures%20and%20the%20impaired%20magnesium%20absorption%20associated%20with%20the%20use%20of%20PPI.%20Thrombocytopenia%2C%20iron%20deficiency%2C%20vitamin%20B12%20deficiency%2C%20rhabdomyolysis%20and%20acute%20interstitial%20nephritis%20have%20also%20been%20reported%20with%20the%20use%20of%20PPIs.%20There%20is%20mounting%20evidence%20that%20PPIs%20are%20associated%20with%20serious%20adverse%20effects.%20Practitioners%20should%20be%20vigilant%20and%20counsel%20patients%20accordingly.%22%2C%22date%22%3A%22Jul%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1586%5C%2F17512433.2013.811206%22%2C%22ISSN%22%3A%221751-2441%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%222VKFDGUB%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Florentin%20and%20Elisaf%22%2C%22parsedDate%22%3A%222012-12-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFlorentin%20M%2C%20Elisaf%20MS.%20Proton%20pump%20inhibitor-induced%20hypomagnesemia%3A%20A%20new%20challenge.%20World%20J%20Nephrol.%202012%20Dec%206%3B1%286%29%3A151%26%23x2013%3B4.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proton%20pump%20inhibitor-induced%20hypomagnesemia%3A%20A%20new%20challenge%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matilda%22%2C%22lastName%22%3A%22Florentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moses%20S%22%2C%22lastName%22%3A%22Elisaf%22%7D%5D%2C%22abstractNote%22%3A%22Proton%20pump%20inhibitors%20%28PPIs%29%20are%20commonly%20used%20in%20clinical%20practice%20for%20the%20prevention%20and%20treatment%20of%20peptic%20ulcer%2C%20gastritis%2C%20esophagitis%20and%20gastroesophageal%20reflux.%20Hypomagnesemia%20has%20recently%20been%20recognized%20as%20a%20side%20effect%20of%20PPIs.%20Low%20magnesium%20levels%20may%20cause%20symptoms%20from%20several%20systems%2C%20some%20of%20which%20being%20potentially%20serious%2C%20such%20as%20tetany%2C%20seizures%20and%20arrhythmias.%20It%20seems%20that%20PPIs%20affect%20the%20gastrointestinal%20absorption%20of%20magnesium.%20Clinicians%20should%20be%20vigilant%20in%20order%20to%20timely%20consider%20and%20prevent%20or%20reverse%20hypomagnesemia%20in%20patients%20who%20take%20PPIs%2C%20especially%20if%20they%20are%20prone%20to%20this%20electrolyte%20disorder.%22%2C%22date%22%3A%22Dec%206%2C%202012%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5527%5C%2Fwjn.v1.i6.151%22%2C%22ISSN%22%3A%222220-6124%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22EZ5PZX6V%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Faulhaber%20et%20al.%22%2C%22parsedDate%22%3A%222013-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFaulhaber%20GAM%2C%20Ascoli%20BM%2C%20Lubini%20A%2C%20Mossmann%20M%2C%20Rossi%20G%2C%20Geib%20G%2C%20et%20al.%20Serum%20magnesium%20and%20proton-pump%20inhibitors%20use%3A%20a%20cross-sectional%20study.%20Rev%20Assoc%20Med%20Bras.%202013%20Jun%3B59%283%29%3A276%26%23x2013%3B9.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Serum%20magnesium%20and%20proton-pump%20inhibitors%20use%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20Adolpho%20Moreira%22%2C%22lastName%22%3A%22Faulhaber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruna%20Maria%22%2C%22lastName%22%3A%22Ascoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriano%22%2C%22lastName%22%3A%22Lubini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e1rcio%22%2C%22lastName%22%3A%22Mossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilherme%22%2C%22lastName%22%3A%22Geib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%5Cu00e2nia%20Weber%22%2C%22lastName%22%3A%22Furlanetto%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20The%20aim%20of%20this%20study%20was%20to%20evaluate%20the%20association%20of%20serum%20magnesium%20levels%20with%20proton%20pump%20inhibitors%20%28PPIs%29%20use%20and%20other%20factors.%5CnMETHODS%3A%20This%20was%20a%20cross-sectional%20study%20of%20151%20patients%20admitted%20with%20acute%20diseases%20in%20the%20Internal%20Medicine%20Division%20of%20the%20Hospital%20de%20Clinicas%20de%20Porto%20Alegre%2C%20after%20the%20exclusion%20of%20conditions%20that%20are%20commonly%20associated%20with%20hypomagnesemia%3A%20diarrhea%3B%20vomiting%3B%20chronic%20alcohol%20use%3B%20severely%20uncompensated%20diabetes%20mellitus%3B%20and%20chronic%20use%20of%20laxatives%2C%20diuretics%20or%20other%20drugs%20causing%20magnesium%20deficiency.%5CnRESULTS%3A%20All%20patients%20had%20normal%20serum%20magnesium%20levels.%20Serum%20albumin%20and%20creatinine%20levels%20were%20positively%20associated%20with%20serum%20magnesium%20levels%2C%20after%20adjusting%20for%20confounders.%20There%20was%20no%20difference%20between%20mean%20serum%20magnesium%20levels%20of%20PPI%20users%20and%20non-users%2C%20nor%20between%20men%20and%20women%3B%20there%20was%20also%20no%20correlation%20among%20age%2C%20serum%20phosphorus%2C%20and%20potassium%20levels%20with%20serum%20magnesium%20levels.%20Limitations%20of%20this%20study%20include%20the%20absence%20of%20an%20instrument%20for%20measuring%20adherence%20to%20PPI%20use%20and%20the%20sample%20size.%5CnCONCLUSION%3A%20The%20association%20of%20PPI%20use%20and%20hypomagnesemia%20is%20uncommon.%20Congenital%20defects%20in%20the%20metabolism%20of%20magnesium%20may%20be%20responsible%20for%20hypomagnesemia%20in%20some%20patients%20using%20this%20drug%20class.%22%2C%22date%22%3A%222013%20May-Jun%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ramb.2012.12.007%22%2C%22ISSN%22%3A%220104-4230%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22ZPBT2NW3%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lemon%22%2C%22parsedDate%22%3A%222013%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ELemon%20TI.%20Proton%20pump%20inhibitors%20and%20hypomagnesemia%20monitoring.%20Int%20J%20Gen%20Med.%202013%3B6%3A675.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proton%20pump%20inhibitors%20and%20hypomagnesemia%20monitoring%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20I%22%2C%22lastName%22%3A%22Lemon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2147%5C%2FIJGM.S51547%22%2C%22ISSN%22%3A%221178-7074%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%2263QKR8ME%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Corleto%20et%20al.%22%2C%22parsedDate%22%3A%222014-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ECorleto%20VD%2C%20Festa%20S%2C%20Di%20Giulio%20E%2C%20Annibale%20B.%20Proton%20pump%20inhibitor%20therapy%20and%20potential%20long-term%20harm.%20Curr%20Opin%20Endocrinol%20Diabetes%20Obes.%202014%20Feb%3B21%281%29%3A3%26%23x2013%3B8.%3C%5C%2Fdiv%3E%5Cn%20%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proton%20pump%20inhibitor%20therapy%20and%20potential%20long-term%20harm%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vito%20Domenico%22%2C%22lastName%22%3A%22Corleto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Festa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilio%22%2C%22lastName%22%3A%22Di%20Giulio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Annibale%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20This%20review%20summarizes%20the%20recent%20literature%20on%20the%20potential%20side-effects%20of%20proton%20pump%20inhibitors%20%28PPIs%29%20and%20known%20interactions%20with%20the%20metabolism%5C%2Fabsorption%20of%20other%20drugs.%5CnRECENT%20FINDINGS%3A%20Data%20confirm%20that%20PPIs%20are%20a%20very%20well%20tolerated%20drug%20class.%20Their%20high%20safety%2C%20efficacy%20and%20wide%20distribution%20lead%20to%20overuse%2C%20inappropriate%20dosage%20or%20excessive%20duration%20of%20treatment.%20Despite%20the%20absorption%20of%20micronutrients%20or%20other%20plausible%20effects%20on%20the%20development%20of%20bacterial%20infections%20linked%20to%20PPI-induced%20hypochlorhydria%2C%20it%20is%20difficult%20to%20demonstrate%20an%20association%20between%20PPI%20and%20specific%20symptoms.%20A%20possible%20negative%20effect%20of%20PPIs%20on%20bone%20integrity%20appears%20weak%2C%20but%20hypomagnesemia%20is%20likely%20a%20PPI%20drug%20class%20effect.%20A%20higher%20risk%20of%20Clostridium%20difficile%20infection%20and%20other%20infectious%20diseases%20such%20as%20small%20intestinal%20bacterial%20overgrowth%20and%20spontaneous%20bacterial%20peritonitis%20remain%20controversial%20in%20PPI%20users.%20However%2C%20the%20careful%20use%20of%20PPIs%20in%20cirrhotic%20or%20otherwise%20fragile%20patients%20is%20mandatory.%20Short-term%20or%20long-term%20PPI%20use%20may%20trigger%20microscopic%20colitis%2C%20and%20the%20management%20of%20this%20condition%20may%20include%20PPI%20withdrawal.%20The%20effect%20of%20PPIs%20on%20stimulating%20exocrine%20or%20endocrine%20gastric%20cell%20proliferation%20is%20poorly%20understood.%20A%20diagnostic%20delay%20or%20masking%20of%20diseases%20such%20as%20gastrinoma%20is%20difficult%20to%20evaluate.%5CnSUMMARY%3A%20Short-term%20standard%20dose%20PPI%20treatment%20is%20low%20risk.%20Long-term%20PPI%20use%20may%20complicate%20health%20conditions%20by%20various%20mechanisms%20linked%20to%20PPIs%20and%5C%2For%20to%20hypochlorhydria.%22%2C%22date%22%3A%22Feb%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FMED.0000000000000031%22%2C%22ISSN%22%3A%221752-2978%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222014-02-09T04%3A32%3A21Z%22%7D%7D%2C%7B%22key%22%3A%224IGNI2J9%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tsoi%20et%20al.%22%2C%22parsedDate%22%3A%222013%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ETsoi%20KKF%2C%20Hirai%20HW%2C%20Sung%20JJY.%20Meta-analysis%3A%20comparison%20of%20oral%20vs.%20intravenous%20proton%20pump%20inhibitors%20in%20patients%20with%20peptic%20ulcer%20bleeding.%20Alimentary%20Pharmacology%20%26amp%3B%20Therapeutics%20%5BInternet%5D.%202013%20%5Bcited%202013%20Aug%2020%5D%3Bn%5C%2Fa-n%5C%2Fa.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.jwatch.org%5C%2Fna31982%5C%2F2013%5C%2F08%5C%2F16%5C%2Fintravenous-vs-oral-proton-pump-inhibitors-bleeding-peptic%3Fquery%3Dpfw-featured%27%3Ehttp%3A%5C%2F%5C%2Fwww.jwatch.org%5C%2Fna31982%5C%2F2013%5C%2F08%5C%2F16%5C%2Fintravenous-vs-oral-proton-pump-inhibitors-bleeding-peptic%3Fquery%3Dpfw-featured%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Meta-analysis%3A%20comparison%20of%20oral%20vs.%20intravenous%20proton%20pump%20inhibitors%20in%20patients%20with%20peptic%20ulcer%20bleeding%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%20F.%22%2C%22lastName%22%3A%22Tsoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20W.%22%2C%22lastName%22%3A%22Hirai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%20Y.%22%2C%22lastName%22%3A%22Sung%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2013%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fapt.12441%22%2C%22ISSN%22%3A%2202692813%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.jwatch.org%5C%2Fna31982%5C%2F2013%5C%2F08%5C%2F16%5C%2Fintravenous-vs-oral-proton-pump-inhibitors-bleeding-peptic%3Fquery%3Dpfw-featured%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222013-08-20T04%3A22%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22KW2NF67U%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ghebremariam%20et%20al.%22%2C%22parsedDate%22%3A%222013-07-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGhebremariam%20YT%2C%20LePendu%20P%2C%20Lee%20JC%2C%20Erlanson%20DA%2C%20Slaviero%20A%2C%20Shah%20NH%2C%20et%20al.%20An%20Unexpected%20Effect%20of%20Proton%20Pump%20Inhibitors%3A%20Elevation%20of%20the%20Cardiovascular%20Risk%20Factor%20ADMA.%20Circulation%20%5BInternet%5D.%202013%20Jul%203%20%5Bcited%202013%20Jul%2019%5D%3B%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fcirc.ahajournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2013%5C%2F07%5C%2F03%5C%2FCIRCULATIONAHA.113.003602%27%3Ehttp%3A%5C%2F%5C%2Fcirc.ahajournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2013%5C%2F07%5C%2F03%5C%2FCIRCULATIONAHA.113.003602%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22An%20Unexpected%20Effect%20of%20Proton%20Pump%20Inhibitors%3A%20Elevation%20of%20the%20Cardiovascular%20Risk%20Factor%20ADMA%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohannes%20T.%22%2C%22lastName%22%3A%22Ghebremariam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paea%22%2C%22lastName%22%3A%22LePendu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerry%20C.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20A.%22%2C%22lastName%22%3A%22Erlanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Slaviero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nigam%20H.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Leiper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20P.%22%2C%22lastName%22%3A%22Cooke%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cu2014Proton%20pump%20inhibitors%20%28PPIs%29%20are%20gastric%20acid%20suppressing%20agents%20widely%20prescribed%20for%20the%20treatment%20of%20gastro-esophageal%20reflux%20disease%20%28GERD%29.%20Recently%2C%20several%20studies%20in%20patients%20with%20acute%20coronary%20syndrome%20%28ACS%29%20have%20raised%20the%20concern%20that%20use%20of%20PPIs%20in%20these%20patients%20may%20increase%20their%20risk%20of%20major%20adverse%20cardiovascular%20events%20%28MACE%29.%20The%20mechanism%20of%20this%20possible%20adverse%20effect%20is%20not%20known.%20Whether%20the%20general%20population%20might%20also%20be%20at%20risk%20has%20not%20been%20addressed.%5CnMethods%20and%20Results%5Cu2014Plasma%20ADMA%20is%20an%20endogenous%20inhibitor%20of%20nitric%20oxide%20synthase%20%28NOS%29.%20Elevated%20plasma%20ADMA%20is%20associated%20with%20increased%20risk%20for%20cardiovascular%20disease%2C%20likely%20due%20to%20its%20attenuation%20of%20the%20vasoprotective%20effects%20of%20endothelial%20NOS.%20We%20find%20that%20PPIs%20elevate%20plasma%20asymmetric%20dimethylarginine%20%28ADMA%29%20level%20and%20reduce%20nitric%20oxide%20%28NO%29%20levels%20and%20endothelium-dependent%20vasodilation%20in%20a%20murine%20model%20and%20ex%20vivo%20human%20tissues.%20PPIs%20increase%20ADMA%20because%20they%20bind%20to%2C%20and%20inhibit%20dimethylarginine%20dimethylaminohydrolase%20%28DDAH%29%2C%20the%20enzyme%20that%20degrades%20ADMA.%5CnConclusions%5Cu2014We%20present%20a%20plausible%20biological%20mechanism%20to%20explain%20the%20association%20of%20PPIs%20with%20increased%20MACE%20in%20patients%20with%20unstable%20coronary%20syndromes.%20Of%20concern%2C%20this%20adverse%20mechanism%20is%20also%20likely%20to%20extend%20to%20the%20general%20population%20using%20PPIs.%20This%20finding%20compels%20additional%20clinical%20investigations%20and%20pharmacovigilance%20directed%20toward%20understanding%20the%20cardiovascular%20risk%20associated%20with%20use%20of%20the%20PPIs%20in%20the%20general%20population.%22%2C%22date%22%3A%222013-07-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.113.003602%22%2C%22ISSN%22%3A%220009-7322%2C%201524-4539%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcirc.ahajournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2013%5C%2F07%5C%2F03%5C%2FCIRCULATIONAHA.113.003602%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222013-07-19T10%3A51%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22ZRFRE8TI%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nasser%20et%20al.%22%2C%22parsedDate%22%3A%222010-02-28%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ENasser%20SC%2C%20Nassif%20JG%2C%20Dimassi%20HI.%20Clinical%20and%20cost%20impact%20of%20intravenous%20proton%20pump%20inhibitor%20use%20in%20non-ICU%20patients.%20World%20J%20Gastroenterol%20%5BInternet%5D.%202010%20Feb%2028%20%5Bcited%202012%20Aug%2014%5D%3B16%288%29%3A982%26%23x2013%3B6.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F20180237%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F20180237%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20and%20cost%20impact%20of%20intravenous%20proton%20pump%20inhibitor%20use%20in%20non-ICU%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soumana%20C%22%2C%22lastName%22%3A%22Nasser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanette%20G%22%2C%22lastName%22%3A%22Nassif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hani%20I%22%2C%22lastName%22%3A%22Dimassi%22%7D%5D%2C%22abstractNote%22%3A%22AIM%5Cn%5CnTo%20assess%20the%20appropriateness%20of%20the%20indication%20and%20route%20of%20administration%20of%20proton-pump-inhibitors%20%28PPIs%29%20and%20their%20associated%20cost%20impact.%5Cn%5Cn%5CnMETHODS%5Cn%5CnData%20collection%20was%20performed%20prospectively%20during%20a%206-mo%20period%20on%20340%20patients%20who%20received%20omeprazole%20intravenously%20during%20their%20hospital%20stay%20in%20non-intensive%20care%20floors.%20Updated%20guidelines%20were%20used%20to%20assess%20the%20appropriateness%20of%20the%20indication%20and%20route%20of%20administration.%5Cn%5Cn%5CnRESULTS%5Cn%5CnComplete%20data%20collection%20was%20available%20for%20286%20patients%20which%20were%20used%20to%20assess%20intravenous%20%28IV%29%20PPIs%20utilization.%20Around%2088%25%20of%20patients%20were%20receiving%20PPIs%20for%20claimed%20stress%20ulcer%20prophylaxis%20%28SUP%29%20indication%3B%20of%20which%2C%20only%2017%25%20met%20the%20guideline%20criteria%20for%20SUP%20indication%2C%2014%25%20met%20the%20criteria%20for%20non-steroidal-anti-inflammatory%20drugs-induced%20ulcer%20prophylaxis%2C%20while%20the%20remaining%2069%25%20were%20identified%20as%20having%20an%20unjustified%20indication%20for%20PPI%20use.%20The%20initiation%20of%20IV%20PPIs%20was%20appropriate%20in%2055%25%20of%20patients.%20Half%20of%20these%20patients%20were%20candidates%20for%20switching%20to%20the%20oral%20dosage%20form%20during%20their%20hospitalization%2C%20while%20only%2036.7%25%20of%20these%20patients%20were%20actually%20switched.%20The%20inappropriate%20initiation%20of%20PPIs%20via%20the%20IV%20route%20was%20more%20likely%20to%20take%20place%20on%20the%20medical%20floor%20than%20the%20surgical%20floor%20%2853%25%20vs%2036%25%2C%20P%20%3D%200.003%29.%20The%20cost%20analysis%20associated%20with%20the%20appropriateness%20of%20the%20indication%20for%20PPI%20use%20as%20well%20as%20the%20route%20of%20administration%20of%20PPI%20revealed%20a%20possible%20saving%20of%20up%20to%20%2417%2C732.5%20and%20%2414%2C571%2C%20respectively.%5Cn%5Cn%5CnCONCLUSION%5Cn%5CnThis%20study%20highlights%20the%20over-utilization%20of%20IV%20PPIs%20in%20non-intensive%20care%20unit%20patients.%20Restriction%20of%20IV%20PPI%20use%20for%20justified%20indications%20and%20route%20of%20administration%20is%20recommended.%22%2C%22date%22%3A%22Feb%2028%2C%202010%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221007-9327%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F20180237%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22GKNCQZ2K%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Farrell%20et%20al.%22%2C%22parsedDate%22%3A%222010-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EFarrell%20CP%2C%20Mercogliano%20G%2C%20Kuntz%20CL.%20Overuse%20of%20stress%20ulcer%20prophylaxis%20in%20the%20critical%20care%20setting%20and%20beyond.%20J%20Crit%20Care%20%5BInternet%5D.%202010%20Jun%20%5Bcited%202012%20Aug%2014%5D%3B25%282%29%3A214%26%23x2013%3B20.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F19683892%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F19683892%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Overuse%20of%20stress%20ulcer%20prophylaxis%20in%20the%20critical%20care%20setting%20and%20beyond%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20P%22%2C%22lastName%22%3A%22Farrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giancarlo%22%2C%22lastName%22%3A%22Mercogliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20L%22%2C%22lastName%22%3A%22Kuntz%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%5Cn%5CnPatients%20admitted%20to%20the%20intensive%20care%20unit%20%28ICU%29%20are%20susceptible%20to%20stress%20ulcers.%20We%20hypothesize%20that%20despite%20recommendations%2C%20stress%20ulcer%20prophylaxis%20%28SUP%29%20is%20still%20overused%20in%20the%20ICU%20and%20often%20continued%20after%20resolution%20of%20risk%20factors%20for%20bleeding.%5Cn%5Cn%5CnMETHODS%5Cn%5CnWe%20retrospectively%20studied%20all%20ICU%20admissions%20for%204%20months.%20Risk%20factors%20for%20stress%20ulcer%20bleeding%20were%20collected.%20Patients%20were%20categorized%20into%204%20groups%3A%20%281%29%20%3Eor%3D1%20major%20risk%20factor%3B%20%282%29%20%3Eor%3D1%20minor%20risk%20factors%3B%20%283%29%20no%20risk%20factors%3B%20%284%29%20preadmission%20use%20of%20acid-suppressive%20medication.%20The%20rate%20of%20SUP%20was%20calculated%20by%20group%20during%20ICU%20stay%2C%20on%20transfer%20from%20the%20ICU%2C%20and%20at%20hospital%20discharge.%5Cn%5Cn%5CnRESULTS%5Cn%5CnTwo%20hundred%20ten%20patients%20were%20studied.%20Of%20all%20the%20ICU%20admissions%2C%2087.1%25%20received%20SUP.%20Among%20patients%20with%20no%20risk%20factors%2C%2068.1%25%20were%20placed%20on%20prophylaxis%20on%20ICU%20admission%3B%2060.4%25%20continued%20on%20treatment%20upon%20transfer%20from%20the%20ICU%3B%2031.0%25%20were%20discharged%20home%20on%20an%20agent%20without%20a%20new%20indication.%5Cn%5Cn%5CnCONCLUSIONS%5Cn%5CnAlthough%20judicious%20use%20of%20SUP%20in%20high-risk%20patients%20can%20decrease%20the%20incidence%20of%20gastrointestinal%20bleeding%2C%20inappropriate%20use%20may%20increase%20drug%20reactions%2C%20unnecessary%20hospital%20costs%2C%20and%20personal%20monetary%20burden.%20Our%20findings%20argue%20for%20improvement%20measures%20to%20reduce%20initial%20inpatient%20overuse%20of%20SUP%20and%20to%20prompt%20discontinuation%20before%20hospital%20discharge.%22%2C%22date%22%3A%22Jun%202010%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jcrc.2009.05.014%22%2C%22ISSN%22%3A%221557-8615%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F19683892%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22JXTC8C9Q%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Watson%20et%20al.%22%2C%22parsedDate%22%3A%222006-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EWatson%20TD%2C%20Stark%20JE%2C%20Vesta%20KS.%20Pantoprazole-induced%20thrombocytopenia.%20Ann%20Pharmacother%20%5BInternet%5D.%202006%20Apr%20%5Bcited%202012%20Aug%2014%5D%3B40%284%29%3A758%26%23x2013%3B61.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F16569810%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F16569810%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pantoprazole-induced%20thrombocytopenia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tracy%20D%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20E%22%2C%22lastName%22%3A%22Stark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimi%20S%22%2C%22lastName%22%3A%22Vesta%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%5Cn%5CnTo%20report%202%20cases%20of%20thrombocytopenia%20associated%20with%20pantoprazole%20treatment%20and%20discuss%20existing%20reports%20on%20this%20drug-induced%20adverse%20event.%5Cn%5Cn%5CnCASE%20SUMMARIES%5Cn%5CnThis%20paper%20describes%20the%20course%20of%20thrombocytopenia%20associated%20with%20pantoprazole%2040%20mg%20in%202%20hospitalized%20patients.%20In%20both%20cases%2C%20thrombocytopenia%20appeared%20after%20the%20initiation%20of%20pantoprazole%20and%20rapidly%20improved%20after%20discontinuation%20of%20pantoprazole%2C%20although%20complete%20resolution%20of%20thrombocytopenia%20occurred%20in%20only%20one%20patient%20prior%20to%20discharge%20from%20the%20hospital.%5Cn%5Cn%5CnDISCUSSION%5Cn%5CnThe%20mechanism%20of%20drug-induced%20thrombocytopenia%20is%20often%20poorly%20understood%2C%20and%20proton-pump%20inhibitors%20are%20generally%20not%20strongly%20suspected%20as%20a%20cause%20of%20thrombocytopenia.%20However%2C%20an%20objective%20causality%20assessment%20using%20the%20Naranjo%20probability%20scale%20revealed%20a%20probable%20relationship%20between%20thrombocytopenia%20and%20pantoprazole%20in%20both%20of%20the%20cases.%20It%20is%20unknown%20whether%20this%20is%20a%20class%20effect.%5Cn%5Cn%5CnCONCLUSIONS%5Cn%5CnAlthough%20drug-induced%20thrombocytopenia%20with%20pantoprazole%20appears%20to%20be%20rare%2C%20it%20represents%20a%20potentially%20severe%20adverse%20effect.%20This%20supports%20the%20judicious%20prescribing%20of%20pantoprazole%20and%20possibly%20other%20proton-pump%20inhibitors.%22%2C%22date%22%3A%22Apr%202006%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1345%5C%2Faph.1G384%22%2C%22ISSN%22%3A%221060-0280%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F16569810%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22FQHH6ZMK%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eom%20et%20al.%22%2C%22parsedDate%22%3A%222011-02-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EEom%20CS%2C%20Jeon%20CY%2C%20Lim%20JW%2C%20Cho%20EG%2C%20Park%20SM%2C%20Lee%20KS.%20Use%20of%20acid-suppressive%20drugs%20and%20risk%20of%20pneumonia%3A%20a%20systematic%20review%20and%20meta-analysis.%20CMAJ%20%5BInternet%5D.%202011%20Feb%2022%20%5Bcited%202012%20Aug%2014%5D%3B183%283%29%3A310%26%23x2013%3B9.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F21173070%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F21173070%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20acid-suppressive%20drugs%20and%20risk%20of%20pneumonia%3A%20a%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun-Sick%22%2C%22lastName%22%3A%22Eom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20Y%22%2C%22lastName%22%3A%22Jeon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ju-Won%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eun-Geol%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sang%20Min%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kang-Sook%22%2C%22lastName%22%3A%22Lee%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%5Cn%5CnObservational%20studies%20and%20randomized%20controlled%20trials%20have%20yielded%20inconsistent%20findings%20about%20the%20association%20between%20the%20use%20of%20acid-suppressive%20drugs%20and%20the%20risk%20of%20pneumonia.%20We%20performed%20a%20systematic%20review%20and%20meta-analysis%20to%20summarize%20this%20association.%5Cn%5Cn%5CnMETHODS%5Cn%5CnWe%20searched%20three%20electronic%20databases%20%28MEDLINE%20%5BPubMed%5D%2C%20Embase%20and%20the%20Cochrane%20Library%29%20from%20inception%20to%20Aug.%2028%2C%202009.%20Two%20evaluators%20independently%20extracted%20data.%20Because%20of%20heterogeneity%2C%20we%20used%20random-effects%20meta-analysis%20to%20obtain%20pooled%20estimates%20of%20effect.%5Cn%5Cn%5CnRESULTS%5Cn%5CnWe%20identified%2031%20studies%3A%20five%20case-control%20studies%2C%20three%20cohort%20studies%20and%2023%20randomized%20controlled%20trials.%20A%20meta-analysis%20of%20the%20eight%20observational%20studies%20showed%20that%20the%20overall%20risk%20of%20pneumonia%20was%20higher%20among%20people%20using%20proton%20pump%20inhibitors%20%28adjusted%20odds%20ratio%20%5BOR%5D%201.27%2C%2095%25%20confidence%20interval%20%5BCI%5D%201.11-1.46%2C%20I%282%29%2090.5%25%29%20and%20histamine%282%29%20receptor%20antagonists%20%28adjusted%20OR%201.22%2C%2095%25%20CI%201.09-1.36%2C%20I%282%29%200.0%25%29.%20In%20the%20randomized%20controlled%20trials%2C%20use%20of%20histamine%282%29%20receptor%20antagonists%20was%20associated%20with%20an%20elevated%20risk%20of%20hospital-acquired%20pneumonia%20%28relative%20risk%201.22%2C%2095%25%20CI%201.01-1.48%2C%20I%282%29%2030.6%25%29.%5Cn%5Cn%5CnINTERPRETATION%5Cn%5CnUse%20of%20a%20proton%20pump%20inhibitor%20or%20histamine%282%29%20receptor%20antagonist%20may%20be%20associated%20with%20an%20increased%20risk%20of%20both%20community-%20and%20hospital-acquired%20pneumonia.%20Given%20these%20potential%20adverse%20effects%2C%20clinicians%20should%20use%20caution%20in%20prescribing%20acid-suppressive%20drugs%20for%20patients%20at%20risk.%22%2C%22date%22%3A%22Feb%2022%2C%202011%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1503%5C%2Fcmaj.092129%22%2C%22ISSN%22%3A%221488-2329%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F21173070%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22IJ439RIJ%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pilkington%20et%20al.%22%2C%22parsedDate%22%3A%222012-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EPilkington%20KB%2C%20Wagstaff%20MJD%2C%20Greenwood%20JE.%20Prevention%20of%20gastrointestinal%20bleeding%20due%20to%20stress%20ulceration%3A%20a%20review%20of%20current%20literature.%20Anaesth%20Intensive%20Care%20%5BInternet%5D.%202012%20Mar%20%5Bcited%202012%20Aug%2014%5D%3B40%282%29%3A253%26%23x2013%3B9.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22417019%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22417019%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevention%20of%20gastrointestinal%20bleeding%20due%20to%20stress%20ulceration%3A%20a%20review%20of%20current%20literature%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%20B%22%2C%22lastName%22%3A%22Pilkington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20J%20D%22%2C%22lastName%22%3A%22Wagstaff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20E%22%2C%22lastName%22%3A%22Greenwood%22%7D%5D%2C%22abstractNote%22%3A%22Our%20objective%20was%20to%20audit%20our%20current%20stress%20ulcer%20prophylaxis%20protocol%20%28routine%20prescription%20of%20ranitidine%20and%20early%20enteral%20feeding%29%20by%20identifying%20whether%20routine%20prescription%20of%20histamine-2%20receptor%20antagonists%20or%20proton%20pump%20inhibitors%20as%20prophylaxis%20against%20stress-related%20mucosal%20disease%20and%20subsequent%20upper%20gastrointestinal%20bleeding%20is%20supported%20in%20the%20literature.%20We%20also%20aimed%20to%20ascertain%20what%20literature%20evidence%20supports%20the%20role%20of%20early%20enteral%20feeding%20as%20an%20adjunctive%20prophylactic%20therapy%2C%20as%20well%20as%20to%20search%20for%20burn-patient%20specific%20evidence%2C%20since%20burn%20patients%20are%20at%20high%20risk%20for%20developing%20this%20condition%2C%20with%20the%20aim%20of%20changing%20our%20practice.%20PubMed%20and%20Cochrane%20databases%20were%20searched%20for%20relevant%20articles%2C%20yielding%20seven%20randomised%20controlled%20trials%20comparing%20histamine-2%20receptor%20antagonists%20and%20proton%20pump%20inhibitors%20in%20the%20prevention%20of%20upper%20gastrointestinal%20bleeding%20associated%20with%20stress-related%20mucosal%20disease%20and%20three%20separate%20meta-analyses.%20Despite%20level%201%20clinical%20evidence%2C%20no%20significant%20difference%20in%20efficacy%20between%20histamine-2%20receptor%20antagonists%20and%20proton%20pump%20inhibitor%20treatment%20groups%20was%20demonstrated.%20No%20significant%20difference%20was%20demonstrated%20in%20the%20incidence%20of%20nosocomial%20pneumonia%20between%20the%20two%20drugs%20given%20in%20this%20indication.%20However%2C%20enteral%20feeding%20was%20found%20to%20be%20safe%20and%20effective%20in%20preventing%20clinically%20significant%20upper%20gastrointestinal%20bleeding.%20Patients%20able%20to%20tolerate%20feeds%20demonstrated%20no%20additional%20benefit%20with%20concomitant%20pharmacological%20prophylactic%20therapy.%20Since%20all%20burn%20patients%20at%20the%20Royal%20Adelaide%20Hospital%20are%20fed%20from%20very%20early%20in%20their%20admission%2C%20the%20literature%20suggests%20that%20we%2C%20like%20our%20intensive%20care%20unit%20colleagues%2C%20should%20abolish%20our%20reliance%20on%20pharmacological%20prophylaxis%2C%20the%20routine%20prescription%20of%20which%20is%20not%20supported%20by%20the%20evidence.%22%2C%22date%22%3A%22Mar%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220310-057X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22417019%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22PTT66XIT%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vakil%22%2C%22parsedDate%22%3A%222012-03-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EVakil%20N.%20Prescribing%20proton%20pump%20inhibitors%3A%20is%20it%20time%20to%20pause%20and%20rethink%3F%20Drugs%20%5BInternet%5D.%202012%20Mar%205%20%5Bcited%202012%20Aug%2014%5D%3B72%284%29%3A437%26%23x2013%3B45.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22356286%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22356286%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prescribing%20proton%20pump%20inhibitors%3A%20is%20it%20time%20to%20pause%20and%20rethink%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nimish%22%2C%22lastName%22%3A%22Vakil%22%7D%5D%2C%22abstractNote%22%3A%22Proton%20pump%20inhibitors%20%28PPIs%29%20are%20among%20the%20most%20widely%20used%20agents%20in%20the%20world.%20The%20prevalence%20of%20reflux%20disease%20is%20increasing%2C%20as%20is%20the%20incidence%20of%20oesophageal%20adenocarcinoma%2C%20a%20complication%20that%20is%20strongly%20correlated%20with%20chronic%20reflux%20disease.%20Although%20these%20agents%20are%20generally%20safe%2C%20a%20number%20of%20potential%20side%20effects%20have%20been%20described%20and%20a%20careful%20assessment%20of%20the%20risks%20and%20benefits%20of%20PPI%20therapy%20is%20required%20in%20all%20patients%20being%20prescribed%20long-term%20therapy.%20Overutilization%20of%20PPIs%20is%20a%20problem%20in%20clinical%20practice%20and%20needs%20further%20attention.%20PPI%20use%20has%20been%20associated%20with%20osteoporosis%20and%20bone%20fracture%2C%20hypomagnesaemia%2C%20the%20development%20of%20gastric%20polyps%2C%20enteric%20infections%2C%20interstitial%20nephritis%20and%20pneumonia.%20Patients%20on%20long-term%20therapy%20should%20be%20periodically%20evaluated%20for%20the%20indications%20for%20continued%20therapy.%20Despite%20widespread%20publicity%20in%20the%20lay%20press%2C%20and%20regulatory%20guidance%20regarding%20a%20number%20of%20associations%2C%20the%20evidence%20for%20serious%20side%20effects%20is%20poor%20and%20the%20risk%20of%20confounding%20remains%20a%20real%20possibility%20for%20many%20associations.%20Patients%20are%20more%20concerned%20about%20the%20absolute%20risk%20of%20developing%20a%20complication%20than%20a%20relative%20risk.%20The%20absolute%20risk%20of%20all%20the%20complications%20attributed%20to%20PPIs%20is%20low%20and%20patients%20who%20need%20long-term%20PPI%20therapy%20need%20a%20clear%20discussion%20of%20the%20available%20data%20on%20the%20risk%20of%20therapy%20and%20also%20a%20discussion%20of%20the%20risk%20of%20continued%20reflux.%22%2C%22date%22%3A%22Mar%205%2C%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2165%5C%2F11599320-000000000-00000%22%2C%22ISSN%22%3A%220012-6667%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22356286%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22R8J4C8PD%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ra%20and%20Tobe%22%2C%22parsedDate%22%3A%222004-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3ERa%20A%2C%20Tobe%20SW.%20Acute%20interstitial%20nephritis%20due%20to%20pantoprazole.%20Ann%20Pharmacother%20%5BInternet%5D.%202004%20Jan%20%5Bcited%202012%20Aug%2014%5D%3B38%281%29%3A41%26%23x2013%3B5.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F14742791%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F14742791%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acute%20interstitial%20nephritis%20due%20to%20pantoprazole%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Ra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheldon%20W%22%2C%22lastName%22%3A%22Tobe%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%5Cn%5CnTo%20describe%20what%20is%20believed%2C%20as%20of%20November%204%2C%202003%2C%20to%20be%20the%20first%20case%20published%20in%20the%20literature%20of%20acute%20interstitial%20nephritis%20%28AIN%29%20due%20to%20pantoprazole.%5Cn%5Cn%5CnCASE%20SUMMARY%5Cn%5CnA%2077-year-old%20white%20woman%20presented%20to%20the%20hospital%20with%20elevated%20serum%20creatinine%2C%20oliguria%20for%20the%20past%2024%20hours%2C%20arthralgia%2C%20fatigue%2C%20fever%2C%20and%20bilateral%20flank%20pain.%20The%20patient%20had%20initiated%20treatment%20with%20oral%20pantoprazole%2040%20mg%5C%2Fd%20for%20gastroesophageal%20reflux%202%20months%20prior%20to%20admission.%20After%205%20weeks%20of%20therapy%2C%20she%20stopped%20taking%20pantoprazole%20due%20to%20general%20malaise.%20Upon%20admission%2C%20all%20home%20medications%2C%20including%20pantoprazole%2C%20were%20reinitiated%20based%20on%20the%20patient%27s%20medication%20list.%20Serum%20creatinine%20increased%20to%206.1%20mg%5C%2FdL%20on%20day%204%20of%20admission%20from%20a%20baseline%20of%201.0%20mg%5C%2FdL.%20Pantoprazole%20therapy%20was%20promptly%20discontinued%2C%20and%20prednisone%2040%20mg%5C%2Fd%20was%20initiated.%20Urinalysis%20revealed%20eosinophils%2C%20and%20a%20subsequent%20renal%20biopsy%20confirmed%20a%20diagnosis%20of%20AIN.%20The%20serum%20creatinine%20level%20gradually%20declined%20over%202%20weeks%2C%20and%20the%20patient%20was%20discharged%20home%20with%20a%20serum%20creatinine%20level%20of%201.6%20mg%5C%2FdL.%20The%20Naranjo%20probability%20scale%20suggests%20a%20highly%20probable%20relationship%20between%20AIN%20and%20pantoprazole%20therapy%20in%20this%20patient.%5Cn%5Cn%5CnDISCUSSION%5Cn%5CnDrug%20hypersensitivity%20reactions%20are%20the%20most%20common%20cause%20of%20AIN.%20There%20have%20been%20several%20reported%20cases%20of%20omeprazole-induced%20AIN.%20Although%20there%20are%20very%20few%20prospective%20data%20on%20the%20efficacy%20of%20treatment%20of%20drug-induced%20AIN%2C%20corticosteroids%20may%20have%20a%20role%20in%20recovery%20of%20renal%20function.%20Prednisone%20doses%20of%201%20mg%5C%2Fkg%5C%2Fd%20have%20been%20suggested.%5Cn%5Cn%5CnCONCLUSIONS%5Cn%5CnPhysicians%20should%20be%20aware%20that%20drug-induced%20AIN%20can%20be%20associated%20with%20proton-pump%20inhibitors.%20Early%20detection%20of%20this%20rare%20adverse%20reaction%20may%20prevent%20acute%20renal%20insufficiency.%22%2C%22date%22%3A%22Jan%202004%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1345%5C%2Faph.1D085%22%2C%22ISSN%22%3A%221060-0280%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F14742791%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22G87CTHGW%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Heidelbaugh%20et%20al.%22%2C%22parsedDate%22%3A%222012-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EHeidelbaugh%20JJ%2C%20Metz%20DC%2C%20Yang%20YX.%20Proton%20pump%20inhibitors%3A%20are%20they%20overutilised%20in%20clinical%20practice%20and%20do%20they%20pose%20significant%20risk%3F%20Int%20J%20Clin%20Pract%20%5BInternet%5D.%202012%20Jun%20%5Bcited%202012%20Aug%2014%5D%3B66%286%29%3A582%26%23x2013%3B91.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22607510%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22607510%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Proton%20pump%20inhibitors%3A%20are%20they%20overutilised%20in%20clinical%20practice%20and%20do%20they%20pose%20significant%20risk%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20J%22%2C%22lastName%22%3A%22Heidelbaugh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%20C%22%2C%22lastName%22%3A%22Metz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y-X%22%2C%22lastName%22%3A%22Yang%22%7D%5D%2C%22abstractNote%22%3A%22Proton%20pump%20inhibitors%20are%20highly%20effective%20acid%20suppressants%20with%20decades%20of%20use%20highlighting%20positive%20outcomes%20in%20millions%20of%20patients%20worldwide%2C%20and%20they%20offer%20minimal%20risk%20of%20adverse%20events.%20PPIs%20are%20considered%20overutilised%20when%20prescribed%20without%20an%20appropriate%20indication%2C%20when%20patients%20are%20left%20on%20them%20%27indefinitely%27%20without%20appropriate%20indications%20and%20when%20they%20are%20continued%20after%20being%20utilised%20for%20most%20cases%20of%20hospital%20SUP.%20While%20several%20adverse%20outcomes%20have%20been%20linked%20to%20PPI%20therapy%2C%20most%20data%20are%20from%20retrospective%20observational%20studies%20that%20may%20be%20subject%20to%20confounding%20and%20bias.%22%2C%22date%22%3A%22Jun%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fj.1742-1241.2012.02921.x%22%2C%22ISSN%22%3A%221742-1241%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22607510%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-10-29T21%3A24%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22TCPQ37AI%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bez%20et%20al.%22%2C%22parsedDate%22%3A%222012-03-15%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EBez%20C%2C%20Perrottet%20N%2C%20Zingg%20T%2C%20Leung%20Ki%20EL%2C%20Demartines%20N%2C%20Pannatier%20A.%20Stress%20ulcer%20prophylaxis%20in%20non-critically%20ill%20patients%3A%20a%20prospective%20evaluation%20of%20current%20practice%20in%20a%20general%20surgery%20department.%20Journal%20of%20evaluation%20in%20clinical%20practice%20%5BInternet%5D.%202012%20Mar%2015%20%5Bcited%202012%20Aug%2014%5D%3B%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22420909%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22420909%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Stress%20ulcer%20prophylaxis%20in%20non-critically%20ill%20patients%3A%20a%20prospective%20evaluation%20of%20current%20practice%20in%20a%20general%20surgery%20department%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coraline%22%2C%22lastName%22%3A%22Bez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Perrottet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Zingg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22En-Ling%22%2C%22lastName%22%3A%22Leung%20Ki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Demartines%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Pannatier%22%7D%5D%2C%22abstractNote%22%3A%22Rationale%2C%20aims%20and%20objectives%5Cu2002%20There%20is%20little%20evidence%20regarding%20the%20benefit%20of%20stress%20ulcer%20prophylaxis%20%28SUP%29%20outside%20a%20critical%20care%20setting.%20Overprescription%20of%20SUP%20is%20not%20devoid%20of%20risks.%20This%20prospective%20study%20aimed%20to%20evaluate%20the%20use%20of%20proton%20pump%20inhibitors%20%28PPIs%29%20for%20SUP%20in%20a%20general%20surgery%20department.%20Method%5Cu2002%20Data%20collection%20was%20performed%20prospectively%20during%20an%208-week%20period%20on%20patients%20hospitalized%20in%20a%20general%20surgery%20department%20%2858%20beds%29%20by%20pharmacists.%20Patients%20with%20a%20PPI%20prescription%20for%20the%20treatment%20of%20ulcers%2C%20gastro-oesophageal%20reflux%20disease%2C%20oesophagitis%20or%20epigastric%20pain%20were%20excluded.%20Patients%20admitted%20twice%20during%20the%20study%20period%20were%20not%20reincluded.%20The%20American%20Society%20of%20Health-System%20Pharmacists%20guidelines%20on%20SUP%20were%20used%20to%20assess%20the%20appropriateness%20of%20de%20novo%20PPI%20prescriptions.%20Results%5Cu2002%20Among%20255%20patients%20in%20the%20study%2C%20138%20%2854%25%29%20received%20a%20prophylaxis%20with%20PPI%2C%20of%20which%2086%20%2862%25%29%20were%20de%20novo%20PPI%20prescriptions.%20A%20total%20of%20129%20patients%20%2894%25%29%20received%20esomeprazole%20%28according%20to%20the%20hospital%20drug%20policy%29.%20The%20most%20frequent%20dosage%20was%20at%2040%5Cu2003mg%20once%20daily.%20Use%20of%20PPI%20for%20SUP%20was%20evaluated%20in%2067%20patients.%20A%20total%20of%2053%20patients%20%2879%25%29%20had%20no%20risk%20factors%20for%20SUP.%20Twelve%20and%20two%20patients%20had%20one%20or%20two%20risk%20factors%2C%20respectively.%20At%20discharge%2C%20PPI%20prophylaxis%20was%20continued%20in%2033%25%20of%20patients%20with%20a%20de%20novo%20PPI%20prescription.%20Conclusions%5Cu2002%20This%20study%20highlights%20the%20overuse%20of%20PPIs%20in%20non-intensive%20care%20unit%20patients%20and%20the%20inappropriate%20continuation%20of%20PPI%20prescriptions%20at%20discharge.%20Treatment%20recommendations%20for%20SUP%20are%20needed%20to%20restrict%20PPI%20use%20for%20justified%20indications.%22%2C%22date%22%3A%22Mar%2015%2C%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fj.1365-2753.2012.01838.x%22%2C%22ISSN%22%3A%221365-2753%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22420909%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-08-14T18%3A50%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22VFXH4AVJ%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Janarthanan%20et%20al.%22%2C%22parsedDate%22%3A%222012-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EJanarthanan%20S%2C%20Ditah%20I%2C%20Adler%20DG%2C%20Ehrinpreis%20MN.%20Clostridium%20difficile-Associated%20Diarrhea%20and%20Proton%20Pump%20Inhibitor%20Therapy%3A%20A%20Meta-Analysis.%20Am%20J%20Gastroenterol%20%5BInternet%5D.%202012%20Jul%20%5Bcited%202012%20Aug%2014%5D%3B107%287%29%3A1001%26%23x2013%3B10.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22710578%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22710578%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clostridium%20difficile-Associated%20Diarrhea%20and%20Proton%20Pump%20Inhibitor%20Therapy%3A%20A%20Meta-Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sailajah%22%2C%22lastName%22%3A%22Janarthanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivo%22%2C%22lastName%22%3A%22Ditah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%20G%22%2C%22lastName%22%3A%22Adler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murray%20N%22%2C%22lastName%22%3A%22Ehrinpreis%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%5Cn%5CnClostridium%20difficile-associated%20diarrhea%20%28CDAD%29%20is%20a%20major%20cause%20of%20morbidity%20and%20increasing%20health-care%20costs%20among%20hospitalized%20patients.%20Although%20exposure%20to%20antibiotics%20remains%20the%20most%20documented%20risk%20factor%20for%20CDAD%2C%20attention%20has%20recently%20been%20directed%20toward%20a%20plausible%20link%20with%20proton%20pump%20inhibitors%20%28PPIs%29.%20However%2C%20the%20results%20of%20studies%20on%20the%20association%20between%20CDAD%20and%20PPIs%20remain%20controversial.%20We%20have%20conducted%20a%20meta-analysis%20to%20summarize%20the%20association%20between%20PPIs%20and%20CDAD%20among%20hospitalized%20patients.%5Cn%5Cn%5CnMETHODS%5Cn%5CnA%20systematic%20search%20of%20published%20literature%20on%20studies%20that%20investigated%20the%20association%20between%20PPIs%20and%20CDAD%20from%201990%20to%202010%20was%20conducted%20on%20Medline%20and%20PubMed.%20The%20identified%20articles%20were%20reviewed%20for%20additional%20references.%20The%20most%20adjusted%20risk%20estimates%20were%20extracted%20by%20two%20authors%20and%20summarized%20using%20random%20effects%20meta-analysis.%20We%20also%20conducted%20a%20subgroup%20analysis%20by%20study%20design.%20Publication%20bias%20was%20evaluated%20using%20the%20Begg%20and%20Egger%20tests.%20A%20sensitivity%20analysis%20using%20the%20Duval%20and%20Tweedie%20%5C%22trim-and-fill%5C%22%20method%20has%20also%20been%20performed.%5Cn%5Cn%5CnRESULTS%5Cn%5CnTwenty-three%20studies%20including%20close%20to%20300%2C000%20patients%20met%20the%20inclusion%20criteria.%20There%20was%20a%2065%25%20%28summary%20risk%20estimate%201.69%20with%20a%2095%25%20confidence%20interval%20%28CI%29%20from%201.395%20to%201.974%3B%20P%3C0.000%29%20increase%20in%20the%20incidence%20of%20CDAD%20among%20patients%20on%20PPIs.%20By%20study%20design%2C%20whether%20case-control%20study%20%2817%29%20or%20cohort%20study%20%286%29%2C%20there%20was%20still%20a%20significant%20increase%20in%20the%20incidence%20of%20CDAD%20among%20PPI%20users.%20The%20risk%20estimates%20were%202.31%20%2895%25%20CI%20from%201.72%20to%203.10%3B%20P%3C0.001%29%20and%201.48%20%2895%25%20CI%20from%201.25%20to%201.75%3B%20P%3C0.001%29%20for%20cohort%20and%20case-control%20studies%2C%20respectively.%5Cn%5Cn%5CnCONCLUSIONS%5Cn%5CnThere%20is%20sufficient%20evidence%20to%20suggest%20that%20PPIs%20increase%20the%20incidence%20of%20CDAD.%20Our%20meta-analysis%20shows%20a%2065%25%20increase%20in%20the%20incidence%20of%20CDAD%20among%20PPI%20users.%20We%20recommend%20that%20the%20routine%20use%20of%20PPIs%20for%20gastric%20ulcer%20prophylaxis%20should%20be%20more%20prudent.%20Establishing%20a%20guideline%20for%20the%20use%20of%20PPI%20may%20help%20in%20the%20future%20with%20the%20judicious%20use%20of%20PPIs.%20Further%20studies%2C%20preferably%20prospective%2C%20are%20needed%20to%20fully%20explore%20the%20association%20between%20PPIs%20and%20CDAD.%22%2C%22date%22%3A%22Jul%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fajg.2012.179%22%2C%22ISSN%22%3A%221572-0241%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22710578%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-08-14T18%3A29%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22HA4MSZ95%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Issa%20et%20al.%22%2C%22parsedDate%22%3A%222012-03-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EIssa%20IA%2C%20Soubra%20O%2C%20Nakkash%20H%2C%20Soubra%20L.%20Variables%20Associated%20with%20Stress%20Ulcer%20Prophylaxis%20Misuse%3A%20A%20Retrospective%20Analysis.%20Digestive%20diseases%20and%20sciences%20%5BInternet%5D.%202012%20Mar%2017%20%5Bcited%202012%20Aug%2014%5D%3B%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22427129%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22427129%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Variables%20Associated%20with%20Stress%20Ulcer%20Prophylaxis%20Misuse%3A%20A%20Retrospective%20Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iyad%20A%22%2C%22lastName%22%3A%22Issa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ola%22%2C%22lastName%22%3A%22Soubra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hania%22%2C%22lastName%22%3A%22Nakkash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lama%22%2C%22lastName%22%3A%22Soubra%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Stress%20ulcer%20prophylaxis%20%28SUP%29%20is%20commonly%20used%20in%20hospitals.%20Although%20its%20indications%20are%20better%20delineated%20for%20intensive%20care%20unit%20%28ICU%29%20patients%2C%20its%20use%20in%20non-ICU%20settings%20is%20somewhat%20arbitrary%20and%20based%20on%20judgment.%20OBJECTIVE%3A%20We%20attempted%20to%20assess%20the%20extent%20of%20SUP%20overuse%20in%20our%20hospital.%20We%20also%20carefully%20collected%20and%20analyzed%20several%20variables%20to%20detect%20associations%20governing%20this%20flawed%20behavior%20and%20its%20financial%20burden%20on%20the%20hospital%27s%20budget.%20MATERIALS%20AND%20METHODS%3A%20We%20retrospectively%20analyzed%20charts%20of%20patients%20admitted%20to%20the%20medical%20floor%20of%20a%20tertiary%20referral%20university%20hospital%20over%20a%201%20year%20period.%20All%20adult%20patients%20admitted%20to%20the%20medical%20ward%20who%20received%20at%20least%20one%20dose%20of%20SUP%20were%20included%20and%20reviewed%20for%20a%20multitude%20of%20variables%20in%20addition%20to%20the%20appropriateness%20of%20acid%20suppression%20therapy%20%28AST%29.%20RESULTS%3A%20We%20included%20320%20charts%20and%20found%20that%2092%25%20of%20patients%20admitted%20during%20that%20period%20were%20not%20eligible%20for%20SUP.%20The%20total%20inappropriateness%20of%20SUP%20was%20noted%20to%20be%2058%25%20%28p%5Cu00a0%3D%5Cu00a00.015%29.%20Increasing%20age%20and%20male%20gender%20were%20found%20to%20be%20significant%20variables%20in%20AST%20misuse%20%28p%5Cu00a0%3D%5Cu00a00.045%20and%20p%5Cu00a0%3D%5Cu00a00.010%29%2C%20much%20like%20duration%20of%20hospital%20stay%20%28p%5Cu00a0%3D%5Cu00a00.008%29.%20Comorbidities%20was%20also%20found%20to%20be%20a%20defining%20variable%20for%20AST%20overuse%20%28odds%20ratio%20%5BOR%5D%5Cu00a0%3D%5Cu00a03.27%29.%20Patients%20with%20two%20or%20more%20minor%20risk%20factors%20were%20also%20subjected%20more%20to%20SUP%20inappropriately%20%28OR%5Cu00a0%3D%5Cu00a03.53%29%2C%20in%20addition%20to%20patients%20of%20certain%20specialties%20%28Neurology%2C%20Infectious%20Diseases%2C%20etc.%29.%20Our%20calculated%20financial%20burden%20was%20more%20than%20%2423%2C000%20per%20year%20for%20the%20medical%20floor.%20CONCLUSION%3A%20This%20retrospective%20study%20confirmed%20the%20growing%20suspicion%20that%20SUP%20misuse%20is%20evident%20on%20the%20medical%20floors.%20We%20also%20delineated%20several%20factors%20and%20variables%20associated%20with%20and%20affecting%20SUP%20overuse.%22%2C%22date%22%3A%22Mar%2017%2C%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10620-012-2104-9%22%2C%22ISSN%22%3A%221573-2568%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22427129%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-08-14T18%3A24%3A23Z%22%7D%7D%2C%7B%22key%22%3A%222JFQCTQT%22%2C%22library%22%3A%7B%22id%22%3A858234%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Giuliano%20et%20al.%22%2C%22parsedDate%22%3A%222012-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%20style%3D%5C%22clear%3A%20left%3B%20%5C%22%3E%5Cn%20%20%20%20%3Cdiv%20class%3D%5C%22csl-left-margin%5C%22%20style%3D%5C%22float%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%5C%22%3E1.%3C%5C%2Fdiv%3E%3Cdiv%20class%3D%5C%22csl-right-inline%5C%22%20style%3D%5C%22margin%3A%200%20.4em%200%201.5em%3B%5C%22%3EGiuliano%20C%2C%20Wilhelm%20SM%2C%20Kale-Pradhan%20PB.%20Are%20proton%20pump%20inhibitors%20associated%20with%20the%20development%20of%20community-acquired%20pneumonia%3F%20A%20meta-analysis.%20Expert%20Rev%20Clin%20Pharmacol%20%5BInternet%5D.%202012%20May%20%5Bcited%202012%20Aug%2014%5D%3B5%283%29%3A337%26%23x2013%3B44.%20Available%20from%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22697595%27%3Ehttp%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22697595%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%20%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Are%20proton%20pump%20inhibitors%20associated%20with%20the%20development%20of%20community-acquired%20pneumonia%3F%20A%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Giuliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheila%20M%22%2C%22lastName%22%3A%22Wilhelm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pramodini%20B%22%2C%22lastName%22%3A%22Kale-Pradhan%22%7D%5D%2C%22abstractNote%22%3A%22This%20study%20was%20presented%20at%20the%20American%20College%20of%20Chest%20Physicians%20meeting%20in%20Pittsburgh%20%28PA%2C%20USA%29%20in%20October%202011.%20The%20study%20objective%20was%20to%20evaluate%20the%20association%20of%20proton%20pump%20inhibitors%20%28PPIs%29%20and%20community-acquired%20pneumonia%20%28CAP%29.%20The%20design%20was%20a%20meta-analysis%20of%20nine%20case-controlled%20and%20cohort%20studies.%20120%2C863%20pneumonia%20cases%20from%201987%20to%202006%20were%20included%20in%20the%20meta-analysis.%20PubMed%20and%20Ovid%20Medline%20were%20searched%20from%20inception%20through%20May%202011%20by%20two%20investigators%20independently%20using%20keywords%3A%20PPI%2C%20pneumonia%2C%20CAP%2C%20anti-ulcer%2C%20antacid%2C%20omeprazole%2C%20esomeprazole%2C%20lansoprazole%2C%20pantoprazole%20and%20rabeprazole.%20This%20meta-analysis%20only%20included%20case-controlled%20and%20cohort%20studies%20that%20were%20published%20in%20full%20in%20English%20and%20evaluated%20PPI%20use%20and%20CAP%20incidence.%20Studies%20were%20excluded%20if%20they%20included%20the%20following%20patients%3A%20pediatric%2C%20Helicobacter%20pylori%20treatment%20and%20critically%20ill.%20Bibliographies%20of%20recent%20review%20articles%20and%20systematic%20reviews%20were%20hand-searched.%20Quality%20of%20studies%20was%20assessed%20using%20the%20Newcastle-Ottawa%20Quality%20Assessment%20Scale.%20Two%20investigators%20independently%20extracted%20data%20into%20standardized%20data%20collection%20forms%20that%20were%20confirmed%20by%20a%20third%20investigator.%20Data%20were%20analyzed%20based%20on%20current%20use%20of%20PPIs%2C%20duration%20of%20PPI%20use%20%28%3C30%20days%20or%20%3E180%20days%29%20and%20PPI%20dose%20%28high%20vs%20low%29.%20Overall%20association%20of%20PPI%20and%20CAP%20was%20analyzed%20using%20the%20random%20effects%20model%20%28Comprehensive%20Meta%20analysis%28%5Cu00ae%29%20Version%202.0%29.%20Nine%20studies%20met%20all%20criteria%20for%20the%20primary%20outcome.%20Newcastle-Ottawa%20Quality%20Assessment%20Scale%20scores%20ranged%20from%204%20to%208%20out%20of%209.%20Current%20use%20of%20PPIs%20%28odds%20ratio%20%5BOR%5D%3A%201.39%3B%2095%25%20CI%3A%201.09-1.76%29%2C%20PPI%20use%20%3C30%20days%20%28OR%3A%201.65%3B%2095%25%20CI%3A%201.25-2.19%29%2C%20PPI%20high%20dose%20%28OR%3A%201.50%3B%2095%25%20CI%3A%201.33-1.68%29%20and%20PPI%20low%20dose%20%28OR%3A%201.17%3B%2095%25%20CI%3A%201.11-1.24%29%20were%20significantly%20associated%20with%20CAP.%20There%20was%20no%20association%20between%20CAP%20and%20PPI%20use%20%3E180%20days%20%28OR%3A%201.10%3B%2095%25%20CI%3A%201.00-1.21%29.%20In%20conclusion%2C%20patients%20currently%20receiving%20PPIs%2C%20particularly%20%3C30%20days%20or%20high%20dose%2C%20showed%20an%20association%20with%20CAP.%20Practitioners%20need%20to%20be%20vigilant%20about%20adverse%20effects%20of%20PPIs%20and%20consider%20alternative%20therapies.%22%2C%22date%22%3A%22May%202012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1586%5C%2Fecp.12.20%22%2C%22ISSN%22%3A%221751-2441%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpubmed%5C%2F22697595%22%2C%22collections%22%3A%5B%22IXBBZN4Q%22%5D%2C%22dateModified%22%3A%222012-08-14T18%3A20%3A24Z%22%7D%7D%5D%7D
1.
Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013 Apr;83(4):553–6.
1.
Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf. 2013 Sep;12(5):709–16.
1.
El-Charabaty E, Saifan C, Abdallah M, Naboush A, Glass D, Azzi G, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013;6:515–8.
1.
Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013 Jul;6(4):443–51.
1.
Florentin M, Elisaf MS. Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol. 2012 Dec 6;1(6):151–4.
1.
Faulhaber GAM, Ascoli BM, Lubini A, Mossmann M, Rossi G, Geib G, et al. Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Rev Assoc Med Bras. 2013 Jun;59(3):276–9.
1.
Lemon TI. Proton pump inhibitors and hypomagnesemia monitoring. Int J Gen Med. 2013;6:675.
1.
Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3–8.
1.
Tsoi KKF, Hirai HW, Sung JJY. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Alimentary Pharmacology & Therapeutics [Internet]. 2013 [cited 2013 Aug 20];n/a-n/a. Available from: http://www.jwatch.org/na31982/2013/08/16/intravenous-vs-oral-proton-pump-inhibitors-bleeding-peptic?query=pfw-featured
1.
Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. An Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor ADMA. Circulation [Internet]. 2013 Jul 3 [cited 2013 Jul 19]; Available from: http://circ.ahajournals.org/content/early/2013/07/03/CIRCULATIONAHA.113.003602
1.
Nasser SC, Nassif JG, Dimassi HI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol [Internet]. 2010 Feb 28 [cited 2012 Aug 14];16(8):982–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20180237
1.
Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care [Internet]. 2010 Jun [cited 2012 Aug 14];25(2):214–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19683892
1.
Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia. Ann Pharmacother [Internet]. 2006 Apr [cited 2012 Aug 14];40(4):758–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16569810
1.
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ [Internet]. 2011 Feb 22 [cited 2012 Aug 14];183(3):310–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21173070
1.
Pilkington KB, Wagstaff MJD, Greenwood JE. Prevention of gastrointestinal bleeding due to stress ulceration: a review of current literature. Anaesth Intensive Care [Internet]. 2012 Mar [cited 2012 Aug 14];40(2):253–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22417019
1.
Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs [Internet]. 2012 Mar 5 [cited 2012 Aug 14];72(4):437–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22356286
1.
Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann Pharmacother [Internet]. 2004 Jan [cited 2012 Aug 14];38(1):41–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14742791
1.
Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract [Internet]. 2012 Jun [cited 2012 Aug 14];66(6):582–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22607510
1.
Bez C, Perrottet N, Zingg T, Leung Ki EL, Demartines N, Pannatier A. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. Journal of evaluation in clinical practice [Internet]. 2012 Mar 15 [cited 2012 Aug 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22420909
1.
Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. Am J Gastroenterol [Internet]. 2012 Jul [cited 2012 Aug 14];107(7):1001–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22710578
1.
Issa IA, Soubra O, Nakkash H, Soubra L. Variables Associated with Stress Ulcer Prophylaxis Misuse: A Retrospective Analysis. Digestive diseases and sciences [Internet]. 2012 Mar 17 [cited 2012 Aug 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22427129
1.
Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol [Internet]. 2012 May [cited 2012 Aug 14];5(3):337–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22697595
8 réponses sur « IPP EVIL »
Ca met le doigt là où ça fait mal : si tu ne le prescrit pas …. ouh ouh ouh ouh honte sur toi ! Ton confrère le fera (en maugréant que tu as sûrement oublié) ….
bah moi je fais en mon âme et conscience ce que je pense être bien… l’intro de ce billet est caricatural, je donne une grande marge au débat pour/contre les IPP. par contre je suis sans pitié lorsque le patient n’a pas d’antécédent franc et qu’il mange.
Coucou NFKB!
Bon, je sais que le blog n’est pas la pour donner des cours particuliers, mais comme tu es un expert en la matiere (pour moi en tout cas >< ) d'anesthesie reanimation, et que tu as fait un post sur les IPP, je vais poser ma question.
Quelles sont les indications de la prevention de l'ulcere de stress notemment aux ECN, et selon (surtout) quelles modalites?
Explications: dans mes sujets d'ECN, je mettais mes IPP en systematique (REA =IPP). Or un amis m'as fait prendre conscience que ce n'etait pas systematique! Interrogation, ect… et je vais pour chercher les dernieres conferences de consensus a ce sujet: http://www.sfar.org/acta/dossier/archives/ca98/html/ca98_26/98_026.htm Voila, par la SFAR, en 1998! pas trouve mieux!
De plus, ils disent clairement que l'on ne met pas d'IPP (sauf ATCD d'ulcere de stress) mais de la ranitidine! Alors que dans plusieurs dossiers, j'ai prevention de l'ulcere de stress par IPP! Alors question: Je fais quoi?
Merci de ta reponse!
La vraie indication c’est la prévention de l’hémorragie liée à l’ulcère et la transfusion qui en découle, c’est ça le vrai problème.
Dans les textbooks il faut être grave pour bénéficier de la prévention :
intubé/ventilé, choqué, avec troubles de coag (grands brûlés ou polytrau sont assez pourvoyeurs)
Les études historiques ont été faites avec ranitidine ou sucralfate. Plus récemment les IPP ont montré qu’ils faisaient aussi bien. Les trois se valent.
http://www.nfkb0.com/wp-content/uploads/2012/08/stress-ulcer-prophylaxis-.pdf
Ma conclusion : c’est un faux problème pour l’ECN. Tu le mets dans le dossier de réa. Si la grille est remaniée par des non spécialistes (comprendre des docteurs normaux pas des pyschopathes fachisants comme moi sur le sujet) y’a aucune raison d’avoir des points en moins en le mettant.
Merci beaucoup… je mettrais donc « Prevention de l’ulcere de stress par IPP » et non par anti H2… > 3, simplement alcoolique, pas d’autre fdr associe a un ipp (sachant que la ranitidine est moins « puissante » et donc certainement moins iatrogene, et dans les reco de la sfar fait aussi bien!…. Vivement que ce concours soit fini! Je le fais la mais aussi merci pour les posts sur l’Anesthesie, je les copies colle dans un word, et des que j’ai fini mon ecn je commencerais a les etudier serieusement!
[…] l’IPP prescrit comme un réflexe dans 1000 situations où les patients n’en ont pas […]
Bonjour,
Juste encore un article du NEJM sur l’absence de bénéfice du pantoprazole préventif sur la mortalité en réanimation: https://www.nejm.org/doi/10.1056/NEJMoa1714919
Bonne journée!
oui merci ! et les collègues américains ont fait d’excellent billets de blog sur le sujet (même s’ils sont plutôt pour finalement)
http://emcrit.org/pulmcrit/sup-icu/